Compare Las Vegas Sands Corp. (LVS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs 10X Genomics Inc — how do they compare? Las Vegas Sands Corp. trades at $36.23 (market cap $23.38B), while 10X Genomics Inc trades at $81.8 (market cap $10.07B). The key difference: Las Vegas Sands Corp. is far larger — about 2.3× 10X Genomics Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 72 Days and 10X Genomics Inc for 92 Days on average.
| LVS | TXG | |
|---|---|---|
Market Cap | $23.38B | $10.07B |
Volume | 6,994,661 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $97.74 |
52-Week Low | $35.81 | $11.48 |
Typical Hold Time | 72 Days | 92 Days |
Enterprise Value | $35.27B | $9.59B |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $35.81, down 1.38% today, with a bearish technical signal despite bullish oscillators. The company shows strong fundamentals with 2025 revenue of $13.02B and net income of $1.63B, supported by consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 59% buy ratings and a $59.78 price target, representing 67% upside potential from current levels.
LVS presents compelling value with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). Key risks include high debt levels (debt-to-asset ratio 73.15%) and sensitivity to Macao gaming regulations. The stock's current discount to analyst targets offers significant upside if operational momentum continues.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
